Therefore, the interaction between TAMs and TME may contribute to anti–PD≥1 therapy resistance in cancer, providing a theoretical basis for the combination use of targeting macrophages and anti–PD≥1/PD≥L1 therapy. Here, CD274 is linked to cancer.